ADIL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
52.0M
+2499.3%
2.0M
+6.2%
1.9M
+6.9%
1.8M
-6.3%
1.9M
R&D
46.6M
+10679.6%
432.5K
-30.2%
619.4K
+18.9%
521.1K
-28.8%
732.0K
SG&A
5.4M
+244.2%
1.6M
+23.9%
1.3M
+1.8%
1.2M
+8.1%
1.1M
Operating Income
-52025000
-2499.3%
-2001481
-6.2%
-1885379
-6.9%
-1764078
+6.3%
-1882000
EBITDA
-52025141
-2499.5%
-2001340
-6.2%
-1885237
-6.9%
-1763937
+6.3%
-1882141
Net Income
-51989000
-2470.7%
-2022392
-1.3%
-1996163
-11.3%
-1793651
+8.4%
-1958000
EPS (Basic)
$-11.25
-660.1%
$-1.48
$-2.00
+56.6%
$-4.61
EPS (Diluted)
$-11.25
-660.1%
$-1.48
$-2.00
+56.6%
$-4.61
Shares (Diluted)
4.6M
+237.3%
1.4M
886.9K
+108.7%
424.9K
Adial Pharmaceuticals (ADIL) — Financials